Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEPHEN D GRUBB

Allopathic & Osteopathic Physicians Family Medicine

NPI
1689672784
CMS profile
348327
Location
LITTLE RIVER, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,358.20

120 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,358.20 120

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEPHEN D GRUBB

NPI 1689672784 · CMS profile ID 348327

Allopathic & Osteopathic Physicians / Family Medicine

LITTLE RIVER, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1689672784?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEPHEN D GRUBB, NPI 1689672784, CMS profile ID 348327. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689672784?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). STEPHEN D GRUBB, NPI 1689672784, CMS profile ID 348327. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689672784?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
STEPHEN D GRUBB, NPI 1689672784, CMS profile ID 348327, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1689672784?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

120 matching records · $2,358.20 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 120 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–120 of 120.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $11.1003/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001074021 CMS
GlaxoSmithKline, LLC. $18.0703/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001077017 CMS
Janssen Pharmaceuticals, Inc $13.8103/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988079917 CMS
ABBVIE INC. $14.2003/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997396781 CMS
GlaxoSmithKline, LLC. $18.8603/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001076359 CMS
Novo Nordisk Inc $23.6003/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001124029 CMS
ABBVIE INC. $128.7602/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997396779 CMS
Amgen Inc. $13.6102/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020681657 CMS
Merck Sharp & Dohme LLC $17.4002/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048923351 CMS
ABBVIE INC. $3.4302/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997396777 CMS
Lilly USA, LLC $7.1102/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032310615 CMS
Sumitomo Pharma America, Inc. $26.2002/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030922661 CMS
Amgen Inc. $12.0202/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020144623 CMS
ABBVIE INC. $1.8601/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997396775 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.6901/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000082857 CMS
Lilly USA, LLC $8.5001/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032310607 CMS
Amgen Inc. $15.8201/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020144627 CMS
AstraZeneca Pharmaceuticals LP $52.7601/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015600293 CMS
Lilly USA, LLC $16.7301/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032354687 CMS
ABBVIE INC. $2.9001/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997396773 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,163.76 228
PY2020 $3,173.34 224
PY2021 $4,224.75 276
PY2022 $2,733.00 171
PY2023 $2,358.20 120
PY2024 $1,492.87 86
PY2025 $1,482.90 68

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,684.09 1
PY2025 Principal investigator $1,133,096.44 42
PY2024 Recipient $233,108.80 4
PY2024 Principal investigator $473,034.26 21
PY2023 Principal investigator $231,019.54 9
PY2022 Principal investigator $91,999.41 4
PY2021 Principal investigator $383,583.34 25
PY2020 Principal investigator $593,888.54 37
PY2019 Principal investigator $515,714.84 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $14,662.00 12/27/2025 Non-covered Recipient Entity
Little River Clinical Research LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228745812
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,803.63 12/03/2025 Non-covered Recipient Entity
LITTLE RIVER CLINICAL RESEARCH LLC
IS354CS15 No dispute reported 06/30/2026 1246791013
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Main Street Physicians Care
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725040
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Main Street Physicians Care
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725042
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Main Street Physicians Care
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725636
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Main Street Physicians Care
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725834
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Main Street Physicians Care
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228730934
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Main Street Physicians Care
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228730938
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Main Street Physicians Care
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228733582
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Main Street Physicians Care
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228734515
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Main Street Physicians Care
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228735299
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Main Street Physicians Care
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228735801
Principal investigator 1 PFIZER INC. $180.80 11/12/2025 Non-covered Recipient Entity
Walker Family Care
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228719831
Principal investigator 1 PFIZER INC. $265.20 11/12/2025 Non-covered Recipient Entity
Walker Family Care
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228728707
Principal investigator 1 Ionis Pharmaceuticals, Inc. $6,654.92 11/07/2025 Non-covered Recipient Entity
LITTLE RIVER CLINICAL RESEARCH LLC
IS354CS15 No dispute reported 06/30/2026 1246790120
Principal investigator 1 Ionis Pharmaceuticals, Inc. $57,567.00 10/16/2025 Non-covered Recipient Entity
LITTLE RIVER CLINICAL RESEARCH LLC
IS354CS9 No dispute reported 06/30/2026 1246789376
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,000.00 10/16/2025 Non-covered Recipient Entity
LITTLE RIVER CLINICAL RESEARCH LLC
IS354CS9 No dispute reported 06/30/2026 1246789379
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,400.00 10/16/2025 Non-covered Recipient Entity
LITTLE RIVER CLINICAL RESEARCH LLC
IS354CS9 No dispute reported 06/30/2026 1246789381
Principal investigator 1 Ionis Pharmaceuticals, Inc. $124,981.39 10/16/2025 Non-covered Recipient Entity
LITTLE RIVER CLINICAL RESEARCH LLC
IS354CS9 No dispute reported 06/30/2026 1246789386
Principal investigator 1 Janssen Research & Development, LLC $17,136.00 10/13/2025 Non-covered Recipient Entity
Little River Clinic Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175269870
Principal investigator 1 Janssen Research & Development, LLC $38,294.00 10/13/2025 Non-covered Recipient Entity
Little River Clinic Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175269900
Principal investigator 1 Janssen Research & Development, LLC $590.00 09/19/2025 Non-covered Recipient Entity
Little River Clinic Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175269845
Principal investigator 1 Janssen Research & Development, LLC $295.00 09/05/2025 Non-covered Recipient Entity
Little River Clinic Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175269877
Principal investigator 1 Ionis Pharmaceuticals, Inc. $229.24 08/06/2025 Non-covered Recipient Entity
LITTLE RIVER CLINICAL RESEARCH LLC
IS354CS9 No dispute reported 06/30/2026 1246786106
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,566.98 08/06/2025 Non-covered Recipient Entity
LITTLE RIVER CLINICAL RESEARCH LLC
IS354CS15 No dispute reported 06/30/2026 1246786220
Principal investigator 1 Eli Lilly and Company $3,138.80 07/28/2025 Non-covered Recipient Entity
LITTLE RIVER CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187886292
Principal investigator 1 Janssen Research & Development, LLC $3,358.00 07/28/2025 Non-covered Recipient Entity
Little River Clinic Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175269892
Principal investigator 1 Janssen Research & Development, LLC $295.00 06/20/2025 Non-covered Recipient Entity
Little River Clinic Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175269822
Principal investigator 1 Janssen Research & Development, LLC $744.00 05/28/2025 Non-covered Recipient Entity
Little River Clinic Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175269829
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 05/20/2025 Non-covered Recipient Entity
Little River Clinic Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175269854
Principal investigator 1 PFIZER INC. $5,200.00 05/20/2025 Non-covered Recipient Entity
Little River Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228775974
Principal investigator 1 Amgen Inc. $174,710.00 04/23/2025 Non-covered Recipient Entity
LITTLE RIVER CLINICAL RESEARCH LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246643582
Principal investigator 1 Janssen Research & Development, LLC $1,736.00 04/17/2025 Non-covered Recipient Entity
Little River Clinic Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175269862
Principal investigator 1 Janssen Research & Development, LLC $6,600.00 03/25/2025 Non-covered Recipient Entity
Little River Clinic Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175269813
Principal investigator 1 Novartis Pharmaceuticals Corporation $41,911.56 02/27/2025 Non-covered Recipient Entity
LITTLE RIVER CLINICAL RESEARCH LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190311719
Principal investigator 1 Janssen Research & Development, LLC $10,186.00 02/19/2025 Non-covered Recipient Entity
Little River Clinic Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175269884
Principal investigator 1 Amgen Inc. $86,256.00 01/29/2025 Non-covered Recipient Entity
MAIN STREET PHYSICIANS CARE,WATERWAY
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246643731
Principal investigator 1 Novartis Pharmaceuticals Corporation $91,491.87 01/27/2025 Non-covered Recipient Entity
MAIN STREET PHYSICIANS CARE
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190311971
Principal investigator 1 Janssen Research & Development, LLC $2,408.00 01/21/2025 Non-covered Recipient Entity
Little River Clinic Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175269837
Recipient Eli Lilly and Company $1,684.09 01/15/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187871777
Principal investigator 1 Eli Lilly and Company $67,029.00 01/07/2025 Non-covered Recipient Entity
LITTLE RIVER CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187884128
Principal investigator 1 Eli Lilly and Company $316,538.00 01/07/2025 Non-covered Recipient Entity
LITTLE RIVER CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187886390
Principal investigator 1 Novartis Pharmaceuticals Corporation $43,517.05 01/06/2025 Non-covered Recipient Entity
MAIN STREET PHYSICIANS
HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease No dispute reported 06/30/2026 1190298444